Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Co-administered Ragwitek and Grastek in Allergic Rhinitis
NCT02256553Phase 4Completed
- Sponsor
- ALK-Abelló
- Start
- Oct 2014
- Primary completion
- Feb 2015
- Modality
- Allergy Immunotherapy
01
Overview
A Phase 4 trial of ambrosia artemisiifolia allergen extract, grass-pollen extract in allergic rhinitis (AR), sponsored by ALK-Abelló. Started Oct 2014; status: completed.
02
Drugs
ambrosia artemisiifolia allergen extractgrass-pollen extract
03
Conditions
allergic rhinitis (AR)
Beyond the preview
Go deeper on NCT02256553.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02256553.